17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery

DISEASE CHARACTERISTICS:

One of the following diagnoses:

Histologically or cytologically confirmed solid tumor*

Unresectable disease

Hodgkin's or non-Hodgkin's lymphoma

Relapsed disease
Failed at least 1 prior therapy
Neoplastic cells are accessible through biopsy NOTE: *Only patients with biopsy-accessible superficial tumors or lymphoma are eligible once the maximum tolerated dose has been determined
No known standard therapy that is potentially curative or definitely capable of extending life expectancy exists
No CNS metastases

PATIENT CHARACTERISTICS:

Age:

18 and over

Performance status:

ECOG 0-2

Life expectancy:

At least 12 weeks

Hematopoietic:

Absolute neutrophil count at least 1,500/mm^3
Platelet count at least 100,000/mm^3
Hemoglobin at least 9 g/dL

Hepatic:

Bilirubin no greater than 2 times upper limit of normal (ULN)
AST no greater than 2.5 times ULN
Alkaline phosphatase no greater than 2 times ULN (5 times ULN if liver involvement)

Renal:

Creatinine no greater than 1.25 times ULN OR
Creatinine clearance at least 60 mL/min

Cardiovascular:

No New York Heart Association class III or IV heart disease

Other:

Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective nonhormonal contraception
No uncontrolled infection
No seizure disorder
No history of serious allergic reaction to eggs

PRIOR CONCURRENT THERAPY:

Biologic therapy:

More than 4 weeks since prior immunotherapy
More than 4 weeks since prior biologic therapy
No concurrent immunotherapy
No concurrent routine or prophylactic use of a colony-stimulating factor (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF])

Chemotherapy:

More than 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas) and recovered from acute and reversible toxic effects
No other concurrent chemotherapy

Endocrine therapy:

No concurrent birth control pills
No concurrent steroids as anti-emetics

Radiotherapy:

More than 4 weeks since prior radiotherapy
No prior radiotherapy to more than 25% of the bone marrow
No prior radiopharmaceuticals
No concurrent radiotherapy

Surgery:

Not specified

Other:

No concurrent 3A4 enzyme inhibitors (e.g., verapamil, erythromycin, miconazole, or ketoconazole)
No concurrent investigational ancillary therapy
No concurrent enrollment in another study involving a pharmacologic agent (e.g., drugs, biologics, immunotherapy approaches, or gene therapy) for symptom control or therapeutic intent